Evaluation of Th1 & Th2 cytokines secreted in the healing & nonhealing cases of Cutaneous leishmaniasis, treated by Glucantime

Document Type : Research Paper

Authors

1 Associate professor of parasitology, Mashhad university of Medical Sciences, Mashhad, Iran

2 Assistant professor of parasitology, Institute Pastor, Tehran university of Medical Sciences, Tehran, Iran

3 Associate professor of Immunology, Mashhad university of Medical Sciences, Mashhad, Iran

4 Associate professor of Dermatology, Mashhad university of Medical Sciences, Mashhad, Iran

5 MSc of parasitology, Mashhad university of Medical Sciences, Mashhad, Iran

Abstract

Introduction
Cutaneous leishmaniasis is an endemic disease in Iran, the pentavalent antimonials, used for treating this disease; do not show effective enough in the recent years. The cellular immune response caused by T-helper type1 (Th1) cuases protection against leishmaniasis and that of T-helper type2 (Th2) causes the progress of the disease. The aim of this study was evaluating secreted cytokines from peripheral blood mononuclear cells (PBMCs) in healing and nonhealing cases of cutaneous leishmaniasis treated by glucantime and control group to find a treatment policy for nonhealing patients.
Materials and Methods
This descriptive study was conducted in 2006 on the subject of 60 cases of individuals, referred to Vila Clinic and Ghaem Hospital of Mashhad. This study was approved by the local committee of Medical Ethics.The cellular immune response in nonhealing and healing cutaneous leishmaniasis and control group evaluated by measuring the cytokine released by PBMCs when stimulated withLeishmania major antigens and mitogen for 48 h by Enzyme Linked Immuno Sorbent Assay (ELISA).
Results
PBMCs of healing group secreted higher levels of interferon gamma (IFN-γ) than the nonhealing patients (p<0.05), whereas the interleukin 4 (IL-4) levels were higher in the nonhealing group compared to the healing ones (p<0.005).
Conclusion
The results demonstrate that secretion of cytokines that activate Th2 response like IL-4 in nonhealing patients was higher than healing cases and secretion of cytokines which activate Th1 response such as IFN-γ in the healing cases was higher than the nonhealing patients.

Keywords

References

1- Sundar S, Rai M. Laboratory Diagnosis of Visceral Leishmaniasis. Clin Diagn Lab Immunol 2002; 9:951-958K
2- Bottrel RLA, Dutra WO, Martins FA, Gontijo B, Carvalho E, Barral-Netto M, et alKFlow Cytometric Determination
of Cellular Sources and Frequencies of Key Cytokine-Producing Lymphocytes Directed against Recombinant LACK
and Soluble Leishmania Antigen in Human Cutaneous Leishmaniasis. Infect Immun 2001; 69:3232-3239K
3- Habibi GR, Khamesipour A, McMaster WR, Mahboudi F. Cytokine gene expression in healing and non-healing
cases of cutaneous leishmaniasis in response to in vitro stimulation with recombinant gp63 using semi-quantitative RTPCR.
Scand J Immunol 2001; 54:414-420K
4- Faber W, Oskam L, Gool T, Kroon N, Knegt-Junk K J, Hofwegen H,et al. Value of diagnostic techniques for
cutaneous leishmaniasis. J Am Acad Dermatol 2003; 49:70-74.
5- Compos-neto A, Porrozzi R, Greeson K, Coler RN, Webb JR, Seiky YA, et al. Protection against cutaneous
leishmaniasis indused by recombinant Antigens in murine and nonhuman primate models of the human disease. Infect
and Immun 2001; 69:4103-4108.
6- Gary S. Swich from a type 2 to type 1 T helper cell response and cure of stablished leishmania major infection in
mice is induced by combined therapy with IL12 and pentostam. Proc Natl Acad Sci 1995; 92:3142-3146.
7- Croft SL, Sundar S, Fairlamb AH. Drug Resistance in Leishmaniasis. Clin Microbiol Rev 2006 Jan 1; 19:111-26.
8- Awasthi A, Mathur RK, Saha B. Immune response to Leishmania infection. Indian J Med Res 2004; 119:238-258.
9-Abul.K.Abbas, Andrew H.Lichtman and Jordan S. Pober.Cellular and Molecular Immunology. 4th ed. 2000
W.B.Saunders.
10-Ajdary S, Alimohammadian MH, Eslami MB, Kemp K, Kharazmi A. Comparison of the Immune Profile of
Nonhealing Cutaneous Leishmaniasis Patients with Those with Active Lesions and Those Who Have Recovered from
Infection. Infect Immun 2000; 68:1760-4.
11- Constantinescu CS, Hondowicz BD, Elloso MM, Wysocka M, Trinchieri G, Scott P. The role of IL-12 in the maintenance
of an established Th1 immune response in experimental leishmaniasis. Eur J Immunol 1998 ; 28:2227-2233.
12- Mocci S, Coffman RL, Induction of a Th2 population from a polarized leishmania specific Th1 population by in
vitro culture with IL-4. J Immunol 1995; 154:3779-3787.
13- Mohajeri M,Shamsian AK,Shakery MT,Raesolmohadesin M,MahmodiM.Role of TCD4+Cells and their Cytokines
in response to treatment in cuataneous Leshmaniasis.Med J Mashad Uni Med Sci 2006;90:379-386. 
 
14- Anderson CF, Oukka M, Kuchroo VJ, Sacks D. CD4+CD25-Foxp3- Th1 cells are the source of IL-10-mediated
immune suppression in chronic cutaneous leishmaniasis. J Exp Med 2007; 204:285-297K
15- Rogers KA, Titus RG. The human cytokine response to Leishmania major early after exposure to the parasite in
vitro. J Parasitol 2004; 90:557-563. 
medical journal of mashhad university of medical sciences
Volume 51, Issue 3 - Serial Number 3
September and October 2007
Pages 149-154

Files

Share

How to cite

Statistics